白内障手術における術後局所抗生物質を伴わない希釈されていない副院内モキシフロキサシンの安全性

この研究の目的は、追加の術後局所抗生物質を使用せずに白内障手術患者における術後眼内炎の予防に対する希釈されていない0.5％副系副系のモキシフロキサシンの安全性を評価することです。2012年6月から2015年5月まで、ジョンA.モランアイセンターで単一の外科医（B.A.）が行うすべての水晶体乳化白ulsificationは、遡及的にレビューされました。2012年6月から2014年4月まで、患者は術後0.5％の局所0.5％を投与されました。2014年5月から2015年5月まで、すべての患者は術後抗生物質なしで系統的にモキシフロキサシンを投与されました。追跡期間は手術後1か月後でした。術前の視力と術後の視力、角膜浮腫、および前房の反応を記録し、2つのグループ間で比較しました。384 cataract surgeries were performed during the study period.None of the 384 eyes in the study developed endophthalmitis.Of those 384 eyes, 222 were included in the study for analysis based on the inclusion and exclusion criteria.131 were part of the topical antibiotic group and 91 were part of the intracameral group.術後1日での矯正されていない視力の違い（p = 0.595）および術後1か月での最良の矯正視力（p = 0.099）は統計的に有意ではありませんでした。術後1日での角膜浮腫（p = 0.370）および前房反応（p = 0.069）の違いは、術後1か月での角膜浮腫（p = 0.512）および前脳房反応（p = 0.512）も統計的に有意ではありませんでした。希釈されていない0.5％のモキシフロキサシンは、患者の転帰に悪影響を与えることなく眼内炎を予防するために、術後抗生物質の追加の追加の抗生物質予防を追加せずに、白内障手術後に系統内に安全に注入できます。

The objective of this study is to evaluate the safety of undiluted 0.5 % intracameral moxifloxacin for postoperative endophthalmitis prophylaxis in cataract surgery patients without the use of additional postoperative topical antibiotics. All phacoemulsification cataract surgeries performed by a single surgeon (B.A.) at the John A. Moran Eye Center from June 2012 to May 2015 were reviewed retrospectively. From June 2012 to April 2014, patients were given topical 0.5 % moxifloxacin postoperatively. From May 2014 to May 2015, all patients were given moxifloxacin intracamerally with no antibiotics postoperatively. The follow-up period was 1 month after surgery. Preoperative visual acuity and postoperative visual acuity, corneal edema, and anterior chamber reaction were recorded and compared between the two groups. 384 cataract surgeries were performed during the study period. None of the 384 eyes in the study developed endophthalmitis. Of those 384 eyes, 222 were included in the study for analysis based on the inclusion and exclusion criteria. 131 were part of the topical antibiotic group and 91 were part of the intracameral group. The differences in uncorrected visual acuity at 1 day postoperatively (p = 0.595) and best corrected visual acuity at 1 month postoperatively (p = 0.099) were not statistically significant. Differences in corneal edema (p = 0.370) and anterior chamber reaction (p = 0.069) at 1 day postoperatively and corneal edema (p = 0.512) and anterior chamber reaction (p = 0.512) at 1 month postoperatively were also not statistically significant. Undiluted 0.5 % moxifloxacin can be safely injected intracamerally following cataract surgery without additional postoperative antibiotic prophylaxis to prevent endophthalmitis without adverse effects on patient outcomes.